Druggable oncogene fusions in invasive mucinous lung adenocarcinoma

Clinical Cancer Research

Volumn 20, Issue 12, 2014, Pages 3087-3093

  Nakaoku, Takashi ^a,c   Tsuta, Koji ^a   Ichikawa, Hitoshi ^a   Shiraishi, Kouya ^a   Sakamoto, Hiromi ^a   Enari, Masato ^a   Furuta, Koh ^a   Shimada, Yoko ^a   Ogiwara, Hideaki ^a   Watanabe, Shun Ichi ^a   Nokihara, Hiroshi ^a   Yasuda, Kazuki ^b   Hiramoto, Masaki ^b   Nammo, Takao ^b   Ishigame, Teruhide ^d   Schetter, Aaron J ^d   Okayama, Hirokazu ^d   Harris, Curtis C ^d   Kim, Young Hak ^c   Mishima, Michiaki ^c   Yokota, Jun ^a,e   Yoshida, Teruhiko ^a   Kohno, Takashi ^a   more..

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b Research Institute   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d NATIONAL CANCER INSTITUTE   (United States)

^e Institute of Predictive and Personalized Medicine of Cancer IMPPC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CD74 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; HYBRID PROTEIN; K RAS PROTEIN; NEU DIFFERENTIATION FACTOR; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; RNA; TRANSCRIPTOME; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; RAS PROTEIN;

3T3 CELL LINE; ADULT; AGED; ARTICLE; CARCINOGENICITY; COHORT ANALYSIS; CONTROLLED STUDY; EZR-ERBB4 GENE; FEMALE; FUSION GENE; GENE; GENE MUTATION; GENE PRODUCT; GENE SEQUENCE; HUMAN; KIAA1468-RET GENE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; RNA SEQUENCE; SLC3A2 GENE; TRIM24-BRAF GENE; ADENOCARCINOMA, MUCINOUS; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL TRANSFORMATION; DRUG EFFECTS; FOLLOW UP; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MOUSE; MUTATION; NUDE MOUSE; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR INVASION;

ADENOCARCINOMA, MUCINOUS; AGED; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84902682450     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0107     Document Type: Article

References (27)

1. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012;18:349-51.
2. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013;31:1105-11.
3. Gautschi O, Zander T, Keller FA, Strobel K, Hirschmann A, Aebi S, et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013;8:e43-4.
4. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, et al. Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas. Cancer Discov 2013;3:630-5.
5. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18:378-81.
6. Mano H. ALKoma: a cancer subtype with a shared target. Cancer Discov 2012;2:495-502.
7. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4.
8. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18:375-7.
9. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012;22:436-45.
10. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013;31:1097-104.
11. Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K. RET fusion gene: Translation to personalized lung cancer therapy. Cancer Sci 2013;104:1396-400.
12. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013;31:992-1001.
13. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85.
14. Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, et al. The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer 2013;81:371-6.
15. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, et al. The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438-46.
16. Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-64.
17. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. World Health Organization classification of tumors: Pathology and genetics, tumours of lung, pleura, thymus and heart. Lyon, France: IARC Press; 2004.
18. Kim D, Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 2011;12:R72.
19. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 2003;284:14-30. (Pubitemid 36335807)
20. Fleck D, van Bebber F, Colombo A, Galante C, Schwenk BM, Rabe L, et al. Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. J Neurosci 2013;33:7856-69.
21. Dislich B, Lichtenthaler SF. The membrane-bound aspartyl protease BACE1: molecular and functional properties in Alzheimer's disease and beyond. Front Physiol 2012;3:8.
22. Majem M, Pallares C. An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clin Transl Oncol 2013;15:343-57.
23. Perez EA, Spano JP. Current and emerging targeted therapies for metastatic breast cancer. Cancer 2012;118:3014-25.
24. Nelson V, Ziehr J, Agulnik M, Johnson M. Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC. Onco Targets Ther 2013;6:135-43.
25. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, et al. Rearrangements of theRAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010;16:793-8.
26. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.
27. Kettle R, Simmons J, Schindler F, Jones P, Dicker T, Dubois G, et al. Regulation of neuregulin 1beta1-induced MUC5AC and MUC5B expression in human airway epithelium. Am J Respir Cell Mol Biol 2010;42:472-81.